Marcia Weaver holds a PhD in economics and an MA in Public Policy from the University of Chicago. She specializes in cost-effectiveness analysis and has published 70 peer-reviewed articles. At the Institute for Health Metrics and Evaluation, she is leading the research team on cost-effectiveness analyses of interventions to reduce the burden of disease.
Professor Weaver was Principal Investigator for the Integrated Infectious Disease Capacity Building Evaluation (IDCAP), which was awarded to Accordia Global Health Foundation by the Bill & Melinda Gates Foundation. IDCAP was a cluster randomized trial implemented by the Infectious Diseases Institute in Uganda to estimate the cost-effectiveness of two methods for building capacity for the prevention and treatment of HIV, malaria, pneumonia, and tuberculosis. In the United States, she has published on cost-effectiveness of interventions for people with HIV and chronic mental illness and substance abuse as part of the HIV/AIDS Treatment Adherence, Health Outcomes, and Cost Study, and on a joint campaign to promote influenza and pneumococcal vaccines.
Professor Weaver also has extensive experience with evaluating the effects of clinical training programs in Botswana, Indonesia, Namibia, South Africa, Thailand, and the Caribbean region. She is proficient with a broad range of methods for measuring the quality of health care and outcomes, such as patient exit interviews, patient service utilization interviews, Medical Outcomes Study short form (SF)-36, observation of clinical practice, standardized patients, facility records and health management information system, clinical vignettes (sometimes referred to as case scenarios), and population-based surveys of mortality among children under 5 years.
Prior to joining the UW faculty, Professor Weaver served as a long-term advisor on health system reform to ministries of health in Niger and Central African Republic.
GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. The Lancet. 23 May 2018.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 14 Sept 2017: 390; 1211–59.